What are the key takeaways for Medtronic PLC ($MDT)?

Medtronic reported Q1 FY2027 revenue of $9,756 million, representing a 13.7% increase year-over-year, driven by broad-based strength across cardiovascular and neuroscience divisions. Diluted EPS came in at $1.14 with net income reaching $1,470 million, reflecting solid operating leverage and a gross margin of 65.2%. The company generated strong cash flows, with operating cash flow of $1,793 million and free cash flow of $1,290 million in the quarter.

Medtronic PLC (MDT) AI Stock Analysis: Earnings, Risks & Summary

Please enable JavaScript to continue using this application.

Latest Report Overview for Medtronic PLC ($MDT)

AI-powered analysis of Medtronic PLC (MDT) stock based on Q3 2026 financial data.

Published: October 9, 2026

Latest Report Overview

Medtronic PLC (MDT) reported For the quarterly period ended July 31, 2026 (Issuer fiscal Q1 FY2027) revenue of $9,756 million with diluted EPS of $1.14 and net income of $1,470 million. Operating margin was 19.5%, and free cash flow was $1,290 million for the period. Management highlighted strong momentum across core medical technology segments, driven by solid demand for cardiovascular and neuroscience innovations, alongside expanding procedural volumes globally. Operating income and cash generation remained robust, with operating cash flow reaching $1,793 million and free cash flow at $1,290 million for the quarter. The company continued to execute on its strategic portfolio reshaping, investing $771 million in research and development to advance proprietary pipeline technologies while returning capital to shareholders through regular dividends and $247 million in common stock repurchases during the period.

Key Takeaways for Medtronic PLC

Medtronic reported Q1 FY2027 revenue of $9,756 million, representing a 13.7% increase year-over-year, driven by broad-based strength across cardiovascular and neuroscience divisions.
Diluted EPS came in at $1.14 with net income reaching $1,470 million, reflecting solid operating leverage and a gross margin of 65.2%.
The company generated strong cash flows, with operating cash flow of $1,793 million and free cash flow of $1,290 million in the quarter.
Research and development investments totaled $771 million, reinforcing Medtronic's commitment to advancing its proprietary medical device pipeline.
Capital return to shareholders remained active, including $247 million in common stock repurchases executed during the period.
Management maintains a disciplined focus on supply chain resilience and navigating regulatory hurdles across global healthcare markets.

What Does Medtronic PLC Do?

Medtronic PLC is a premier global healthcare technology company that develops, manufactures, and markets device-based medical therapies and services. Its comprehensive product portfolio includes cardiac rhythm devices, interventional vascular systems, surgical robotics, advanced surgical instruments, patient monitoring systems, and automated insulin delivery solutions for diabetes management. The company serves a diverse customer base comprising hospitals, clinics, third-party healthcare providers, group purchasing organizations, and individual patients across more than 150 countries, operating primarily through four major segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. With over 90,000 employees globally and annual revenues exceeding $37 billion, Medtronic maintains an extensive international footprint with major manufacturing and R&D facilities worldwide. Medtronic's business model is uniquely differentiated by its deep clinical expertise, entrenched relationships with physicians and hospital networks, and a massive installed base of sophisticated medical hardware that drives recurring demand for proprietary consumables, catheters, sensors, and replacement components.

Growth Drivers for Medtronic PLC

Commercial rollout and global adoption of next-generation pulsed field ablation (PFA) systems for atrial fibrillation treatment.
Expansion of the Hugo RAS (robotic-assisted surgery) platform into international markets and broadened surgical indications.
Continued market penetration of advanced continuous glucose monitoring (CGM) and automated insulin delivery systems in the Diabetes segment.
Growth in structural heart therapies, including transcatheter aortic valve replacement (TAVR) technologies.
Emerging market expansion and increasing healthcare infrastructure investments across Asia-Pacific and Latin America.

Overview AI Summary Charts Financials Valuation

Based on July 31, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Medtronic PLC ($MDT)

Key Takeaways

1.Medtronic reported Q1 FY2027 revenue of $9,756 million, representing a 13.7% increase year-over-year, driven by broad-based strength across cardiovascular and neuroscience divisions.
2.Diluted EPS came in at $1.14 with net income reaching $1,470 million, reflecting solid operating leverage and a gross margin of 65.2%.
3.The company generated strong cash flows, with operating cash flow of $1,793 million and free cash flow of $1,290 million in the quarter.
4.Research and development investments totaled $771 million, reinforcing Medtronic's commitment to advancing its proprietary medical device pipeline.
5.Capital return to shareholders remained active, including $247 million in common stock repurchases executed during the period.
6.Management maintains a disciplined focus on supply chain resilience and navigating regulatory hurdles across global healthcare markets.

What They Do

How They Make Money

Medtronic recognizes revenue primarily upon the shipment or delivery of medical devices and consumables to customers, or over time for certain service and maintenance contracts. The revenue model combines upfront capital sales of sophisticated medical equipment (such as surgical navigation systems, robotic platforms, and imaging systems) with a highly predictable, recurring revenue stream from single-use disposables, catheters, leads, sensors, and replacement parts required to operate the hardware. The business operates across four primary segments: Cardiovascular (featuring cardiac rhythm management, structural heart, and vascular therapies), Neuroscience (cranial and spinal technologies, neuromodulation, and surgical robotics), Medical Surgical (surgical consumables, advanced energy devices, and patient monitoring), and Diabetes (insulin pumps and continuous glucose monitoring sensors). Recurring revenue from consumables and accessories accounts for the vast majority of total sales, providing high revenue visibility and customer retention. Revenue growth is driven by procedural volume recovery, new product introductions in high-growth categories like pulsed field ablation (PFA) and surgical robotics, geographical expansion, and strategic pricing power derived from clinical superiority and high switching costs.

Competitive Position

Medtronic competes in the global medical technology industry against major established players such as Abbott Laboratories, Boston Scientific, Johnson & Johnson, and Stryker. The company maintains significant competitive advantages, including entrenched hospital and physician relationships, massive global scale, deep clinical trial data, and high switching costs due to the critical nature of its medical devices and specialized physician training requirements. From a valuation perspective, Medtronic trades at a P/E ratio of approximately 21.8 and an EV/EBITDA multiple of 16.2, reflecting steady mid-single-digit to high-single-digit growth, strong cash generation, and a defensive healthcare profile relative to peers. Financial trends demonstrate stable gross margins around 65.2% and robust operating margins near 19.5%, underscoring strong pricing power and operational discipline. Key competitive pressures include aggressive rival product launches in high-growth fields like cardiac ablation and structural heart, pricing negotiations by hospital group purchasing organizations (GPOs), and regulatory hurdles. However, Medtronic's diversified portfolio and continuous R&D innovation secure a highly sustainable market position.

Business Strategy & Moat

Medtronic's business strategy centers on strengthening its competitive moat through continuous technological innovation, portfolio optimization, and deepening clinical integration. The company possesses a robust moat built on high switching costs, proprietary intellectual property, and extensive regulatory approvals, which is currently stable to widening as it introduces next-generation platforms like robotic-assisted surgery and advanced cardiac ablation systems. The company's flywheel mechanics rely on introducing innovative hardware systems into hospitals, which creates a captive, long-term installed base that continuously consumes high-margin proprietary consumables and replacement parts, generating steady free cash flow that is reinvested back into R&D and targeted bolt-on acquisitions. Capital allocation is disciplined, balancing robust R&D investment (~$770M quarterly), strategic M&A, debt stewardship, and shareholder returns via dividends and share buybacks ($247M repurchased in the latest quarter). Financial evidence supporting the moat includes stable gross margins (~65%), strong free cash flow conversion exceeding 100% of net income, and high customer retention rates across major hospital networks.

Industry Outlook

The global medical technology industry is experiencing stable growth driven by favorable demographic trends, including an aging global population, rising chronic disease prevalence, and expanding healthcare access in developing economies. Demand for advanced medical devices remains resilient against broader macroeconomic fluctuations due to the essential, non-discretionary nature of life-saving medical procedures. Near-term tailwinds include the ongoing recovery in elective surgical procedural volumes and rapid technological breakthroughs in artificial intelligence integration, robotics, and minimally invasive therapies. Conversely, industry headwinds involve persistent inflationary pressures on labor and raw materials, hospital staffing constraints, and complex, lengthy regulatory approval processes by agencies such as the US FDA and European authorities. The regulatory landscape remains rigorous, with stringent compliance standards governing medical device safety, cybersecurity, and reimbursement policies enacted by government and private payors.

Growth Drivers

•Commercial rollout and global adoption of next-generation pulsed field ablation (PFA) systems for atrial fibrillation treatment.
•Expansion of the Hugo RAS (robotic-assisted surgery) platform into international markets and broadened surgical indications.
•Continued market penetration of advanced continuous glucose monitoring (CGM) and automated insulin delivery systems in the Diabetes segment.
•Growth in structural heart therapies, including transcatheter aortic valve replacement (TAVR) technologies.
•Emerging market expansion and increasing healthcare infrastructure investments across Asia-Pacific and Latin America.

Recent Developments

•Reported Q1 FY2027 revenue of $9,756 million, up 13.7% year-over-year, driven by strong procedural volumes and portfolio demand.
•Executed $247 million in common stock repurchases during the quarter as part of ongoing capital return commitments.
•Continued clinical trial enrollment and regulatory submissions for next-generation cardiac and neurovascular devices.
•Maintained robust R&D investment of $771 million to support pipeline advancement across all four operating segments.
•Advanced strategic supply chain optimization initiatives to enhance operational resilience and gross margin stability.

Catalysts

•Upcoming regulatory approvals and CE mark decisions for next-generation pulsed field ablation and surgical robotics systems.
•Quarterly financial results and earnings conference calls detailing segment performance and margin trajectory.
•Presentation of pivotal clinical trial data at major medical congresses (e.g., ACC, AHA, TCT).
•Potential strategic bolt-on acquisitions or divestitures aimed at portfolio optimization.
•Updates on Medicare reimbursement coding and coverage policies affecting key high-growth medtech categories.

Share Repurchase / Buyback Program

•Repurchased $247 million of common stock during the quarter as part of ongoing capital allocation and shareholder return programs.

RPO & Key Performance Indicators

•Operating cash flow reached $1,793 million, supporting strong liquidity and financial flexibility.
•Free cash flow stood at $1,290 million for the quarter, demonstrating excellent earnings-to-cash conversion.
•Research and development expenditures were maintained at $771 million, reinforcing pipeline investment.

Strengths

•Robust top-line revenue growth of 13.7% YoY to $9,756 million, reflecting strong global demand across core therapeutic areas.
•Solid gross margin of 65.2% demonstrating strong pricing power and product differentiation.
•Excellent cash generation with operating cash flow of $1,793 million and free cash flow of $1,290 million.
•Consistent shareholder returns backed by $247 million in common stock repurchases during the period.
•Massive global scale and diversified portfolio spanning four major healthcare segments, mitigating single-market risks.

AI Benefits & Opportunities

•Integration of artificial intelligence and machine learning into surgical navigation, imaging systems, and robotic-assisted surgery platforms to enhance precision and clinical outcomes.
•Internal operational efficiencies through AI-driven supply chain forecasting, automated administrative workflows, and predictive maintenance of medical equipment.

Risks & Concerns for Medtronic PLC ($MDT)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Medtronic PLC (MDT, filings period ending July 31, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Oct 9, 2026.

Peers of Medtronic PLC (MDT)

STEDeep Dive

TRIBDeep Dive

Side-by-side comparison

STECompare

TRIBCompare

Based on July 31, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Medtronic PLC ($MDT)

Key Takeaways

1.Medtronic reported Q1 FY2027 revenue of $9,756 million, representing a 13.7% increase year-over-year, driven by broad-based strength across cardiovascular and neuroscience divisions.
2.Diluted EPS came in at $1.14 with net income reaching $1,470 million, reflecting solid operating leverage and a gross margin of 65.2%.
3.The company generated strong cash flows, with operating cash flow of $1,793 million and free cash flow of $1,290 million in the quarter.
4.Research and development investments totaled $771 million, reinforcing Medtronic's commitment to advancing its proprietary medical device pipeline.
5.Capital return to shareholders remained active, including $247 million in common stock repurchases executed during the period.
6.Management maintains a disciplined focus on supply chain resilience and navigating regulatory hurdles across global healthcare markets.

What They Do

How They Make Money

Competitive Position

Business Strategy & Moat

Industry Outlook

Growth Drivers

•Commercial rollout and global adoption of next-generation pulsed field ablation (PFA) systems for atrial fibrillation treatment.
•Expansion of the Hugo RAS (robotic-assisted surgery) platform into international markets and broadened surgical indications.
•Continued market penetration of advanced continuous glucose monitoring (CGM) and automated insulin delivery systems in the Diabetes segment.
•Growth in structural heart therapies, including transcatheter aortic valve replacement (TAVR) technologies.
•Emerging market expansion and increasing healthcare infrastructure investments across Asia-Pacific and Latin America.

Recent Developments

•Reported Q1 FY2027 revenue of $9,756 million, up 13.7% year-over-year, driven by strong procedural volumes and portfolio demand.
•Executed $247 million in common stock repurchases during the quarter as part of ongoing capital return commitments.
•Continued clinical trial enrollment and regulatory submissions for next-generation cardiac and neurovascular devices.
•Maintained robust R&D investment of $771 million to support pipeline advancement across all four operating segments.
•Advanced strategic supply chain optimization initiatives to enhance operational resilience and gross margin stability.

Catalysts

•Upcoming regulatory approvals and CE mark decisions for next-generation pulsed field ablation and surgical robotics systems.
•Quarterly financial results and earnings conference calls detailing segment performance and margin trajectory.
•Presentation of pivotal clinical trial data at major medical congresses (e.g., ACC, AHA, TCT).
•Potential strategic bolt-on acquisitions or divestitures aimed at portfolio optimization.
•Updates on Medicare reimbursement coding and coverage policies affecting key high-growth medtech categories.

Share Repurchase / Buyback Program

•Repurchased $247 million of common stock during the quarter as part of ongoing capital allocation and shareholder return programs.

RPO & Key Performance Indicators

•Operating cash flow reached $1,793 million, supporting strong liquidity and financial flexibility.
•Free cash flow stood at $1,290 million for the quarter, demonstrating excellent earnings-to-cash conversion.
•Research and development expenditures were maintained at $771 million, reinforcing pipeline investment.

Strengths

•Robust top-line revenue growth of 13.7% YoY to $9,756 million, reflecting strong global demand across core therapeutic areas.
•Solid gross margin of 65.2% demonstrating strong pricing power and product differentiation.
•Excellent cash generation with operating cash flow of $1,793 million and free cash flow of $1,290 million.
•Consistent shareholder returns backed by $247 million in common stock repurchases during the period.
•Massive global scale and diversified portfolio spanning four major healthcare segments, mitigating single-market risks.

AI Benefits & Opportunities

•Integration of artificial intelligence and machine learning into surgical navigation, imaging systems, and robotic-assisted surgery platforms to enhance precision and clinical outcomes.
•Internal operational efficiencies through AI-driven supply chain forecasting, automated administrative workflows, and predictive maintenance of medical equipment.

Risks & Concerns for Medtronic PLC ($MDT)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

Summary generated on Oct 9, 2026.

Latest Report Overview for Medtronic PLC ($MDT)

AI-powered analysis of Medtronic PLC (MDT) stock based on Q3 2026 financial data.

Published: October 9, 2026

Latest Report Overview

Key Takeaways for Medtronic PLC

Medtronic reported Q1 FY2027 revenue of $9,756 million, representing a 13.7% increase year-over-year, driven by broad-based strength across cardiovascular and neuroscience divisions.
Diluted EPS came in at $1.14 with net income reaching $1,470 million, reflecting solid operating leverage and a gross margin of 65.2%.
The company generated strong cash flows, with operating cash flow of $1,793 million and free cash flow of $1,290 million in the quarter.
Research and development investments totaled $771 million, reinforcing Medtronic's commitment to advancing its proprietary medical device pipeline.
Capital return to shareholders remained active, including $247 million in common stock repurchases executed during the period.
Management maintains a disciplined focus on supply chain resilience and navigating regulatory hurdles across global healthcare markets.

What Does Medtronic PLC Do?

Growth Drivers for Medtronic PLC

Commercial rollout and global adoption of next-generation pulsed field ablation (PFA) systems for atrial fibrillation treatment.
Expansion of the Hugo RAS (robotic-assisted surgery) platform into international markets and broadened surgical indications.
Continued market penetration of advanced continuous glucose monitoring (CGM) and automated insulin delivery systems in the Diabetes segment.
Growth in structural heart therapies, including transcatheter aortic valve replacement (TAVR) technologies.
Emerging market expansion and increasing healthcare infrastructure investments across Asia-Pacific and Latin America.

Medtronic PLC (MDT) AI Stock Analysis: Earnings, Risks & Summary